BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 19, 2009

Primary Completion Date

February 23, 2016

Study Completion Date

February 23, 2016

Conditions

Neoplasms

Interventions

DRUG

Copanlisib (Aliqopa, BAY80-6946)

BAY80-6946 given IV over 1 hour every week for three weeks with a one week break until progression or unacceptable toxicities develop.

Trial Locations (3)

Pittsburgh

Scottsdale

San Antonio